Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E14.97 EPS (ttm)1.03 Insider Own1.50% Shs Outstand302.61M Perf Week-2.83%
Market Cap4.68B Forward P/E13.75 EPS next Y1.12 Insider Trans-19.06% Shs Float293.05M Perf Month-7.82%
Income323.20M PEG0.43 EPS next Q0.19 Inst Own83.20% Short Float5.82% Perf Quarter-25.93%
Sales671.00M P/S6.97 EPS this Y276.40% Inst Trans0.57% Short Ratio5.02 Perf Half Y-24.26%
Book/sh2.61 P/B5.92 EPS next Y10.85% ROA43.80% Target Price29.22 Perf Year-43.14%
Cash/sh1.65 P/C9.35 EPS next 5Y34.50% ROE65.70% 52W Range15.49 - 32.20 Perf YTD-49.18%
Dividend- P/FCF22.68 EPS past 5Y20.50% ROI55.40% 52W High-52.02% Beta2.12
Dividend %- Quick Ratio6.80 Sales past 5Y57.00% Gross Margin96.90% 52W Low-0.26% ATR0.72
Employees372 Current Ratio6.90 Sales Q/Q88.00% Oper. Margin48.20% RSI (14)36.37 Volatility5.25% 3.92%
OptionableYes Debt/Eq0.00 EPS Q/Q393.90% Profit Margin48.20% Rel Volume0.93 Prev Close16.27
ShortableYes LT Debt/Eq0.03 EarningsNov 01 AMC Payout0.00% Avg Volume3.40M Price15.45
Recom2.10 SMA20-9.61% SMA50-13.01% SMA200-29.74% Volume3,570,358 Change-5.04%
Sep-17-18Initiated Goldman Neutral $22
Sep-10-18Initiated Morgan Stanley Underweight $19
May-11-18Reiterated Needham Buy $33 → $30
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Oct-22-18 06:45AM  Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma Business Wire -5.04%
Oct-20-18 08:45AM  Exelixis Announces Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib in Patients with Advanced Renal Cell Carcinoma Business Wire
Oct-19-18 08:16AM  Why Merck's Latest Success Means Trouble for Exelixis Inc. Motley Fool
Oct-18-18 04:05PM  Exelixis to Release Third Quarter 2018 Financial Results on Thursday, November 1, 2018 Business Wire
Oct-17-18 02:27PM  5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage InvestorPlace
08:30AM  Report: Exploring Fundamental Drivers Behind Bellicum Pharmaceuticals, Social Reality, Exelixis, Edgewell Personal Care, Cronos Group, and Acacia Communications New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-11-18 03:31PM  Tech and biotech on collision course, squeezed by the Peninsula's limited space American City Business Journals
Oct-08-18 06:05PM  Cabozantinib to Be Featured in 13 Presentations at ESMO 2018 Congress Business Wire
10:10AM  Why the Earnings Surprise Streak Could Continue for Exelixis (EXEL) Zacks
08:00AM  Exelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy Business Wire
Oct-07-18 01:00PM  3 Small Biotech Stocks to Watch in the Fourth Quarter TheStreet.com
Oct-05-18 11:00AM  Liver Cancers Rising - Stocks to Watch ACCESSWIRE
Oct-03-18 07:33PM  Top 5 Biotech Stocks for 2018 Investopedia
03:37PM  How Did Exelixis Incs (NASDAQ:EXEL) 42% ROE Fare Against The Industry? Simply Wall St.
08:21AM  3 Top Mid-Cap Stocks to Buy in October Motley Fool
Sep-25-18 04:05PM  Exelixis to Present at the Cantor Fitzgerald Global Healthcare Conference on October 2, 2018 Business Wire
Sep-24-18 04:49PM  Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx Zacks
Sep-23-18 06:33AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Sep-21-18 08:51AM  The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding Benzinga
01:32AM  Exelixis Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma Business Wire
Sep-20-18 04:42PM  Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada Zacks
Sep-19-18 02:38PM  7 Biotech Stocks to Buy Now InvestorPlace
07:32AM  Exelixis Partner Ipsen Announces Health Canadas Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma Business Wire
Sep-12-18 08:00AM  Today's Research Reports on Trending Tickers: Gilead Sciences and Exelixis ACCESSWIRE
Sep-11-18 04:56PM  Why SandRidge Energy, Sonos, and Exelixis Slumped Today Motley Fool -7.77%
Sep-10-18 04:10PM  A Double Pair Trade: Morgan Stanley Buys 2 Biotechs, Sells 2 Others Benzinga
08:45AM  Exelixis' Cabometyx Recommended by NCCN for All Types of RCC Zacks
Sep-07-18 08:00AM  Exelixis Announces New Recommendations for CABOMETYX® (Cabozantinib) Tablets in Updated National Comprehensive Cancer Network Clinical Practice Guidelines Business Wire
Sep-05-18 04:05PM  Exelixis to Present at the Morgan Stanley Global Health Care Conference on September 12, 2018 Business Wire
Sep-01-18 12:06AM  Exelixis (EXEL) Down 14.1% Since Last Earnings Report: Can It Rebound? Zacks
Aug-31-18 01:33PM  3 Stocks That Could Put Apple's Returns to Shame Motley Fool
Aug-30-18 08:54AM  Is Beaten-Down Exelixis, Inc. a Buy Now? Motley Fool
08:28AM  What Are Analysts Saying About The Future Of Exelixis Incs (NASDAQ:EXEL)? Simply Wall St.
Aug-28-18 08:00AM  Today's Research Reports on Trending Tickers: Exelixis and bluebird bio ACCESSWIRE
Aug-23-18 10:30AM  Recent Analysis Shows KB Home, Sleep Number, Exelixis, Sprint, PayPal, and Halozyme Therapeutics Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-21-18 08:00AM  Todays Research Reports on Stocks to Watch: Seven Stars Cloud and Exelixis ACCESSWIRE
Aug-20-18 10:03AM  8 Undervalued Biotech Stocks to Watch InvestorPlace -7.86%
Aug-16-18 08:44AM  Better Speculative Biotech Stock: Amarin Corporation vs. Geron Corporation Motley Fool
Aug-14-18 01:40PM  Edited Transcript of EXEL earnings conference call or presentation 1-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
09:36AM  13 of the Cheapest Healthcare Stocks Motley Fool
Aug-06-18 10:30AM  Exelixis Gets the Patients Eventually Motley Fool
Aug-02-18 12:50PM  Here's Why Exelixis Stock Jumped Higher Today Motley Fool +9.16%
07:08AM  Exelixis (EXEL) Earnings Beat on Strong Cabometyx in Q2 Zacks
Aug-01-18 07:20PM  Exelixis (EXEL) Q2 Earnings and Revenues Surpass Estimates Zacks
06:15PM  Exelixis: 2Q Earnings Snapshot Associated Press
04:05PM  Exelixis Announces Second Quarter 2018 Financial Results and Provides Corporate Update Business Wire
02:56PM  3 Top Mid-Cap Stocks to Buy Right Now Motley Fool
Jul-27-18 04:03PM  Is Exelixis (EXEL) Poised for a Beat Again in Q2? Zacks
Jul-25-18 09:15AM  Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies, Inc. Motley Fool
Jul-17-18 04:05PM  Exelixis to Release Second Quarter 2018 Financial Results on Wednesday, August 1, 2018 Business Wire
Jul-04-18 05:00PM  Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine Business Wire
Jun-28-18 08:51AM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
Jun-27-18 08:42AM  Exelixis (EXEL) Jumps: Stock Rises 8% Zacks
08:00AM  Exelixis to Be Added to the S&P MidCap 400 Index Business Wire
Jun-26-18 08:34AM  Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results Benzinga +7.98%
08:05AM  Better Buy: Exelixis, Inc. vs. Immunogen, Inc. Motley Fool
08:00AM  Today's Research Reports on Trending Tickers: Exelixis and Zafgen ACCESSWIRE
Jun-25-18 06:23PM  Copart Set to Join S&P 500; Exelixis to Join S&P MidCap 400; Clarifications to S&P U.S. Indices Methodology PR Newswire
Jun-21-18 08:25AM  Today's Research Reports on Trending Tickers: bluebird bio and Exelixis ACCESSWIRE
07:30AM  Exelixis Inc (NASDAQ:EXEL) Has Attractive Fundamentals, Heres Why Simply Wall St.
07:25AM  Stock Performance Review on Exelixis and Three Other Biotech Stocks ACCESSWIRE
Jun-19-18 07:05PM  Cramer's lightning round: GE's CEO was dealt 'one of the ... CNBC Videos
06:50PM  Cramer's lightning round: GE's CEO was dealt 'one of the worst hands that anyones ever been given' CNBC
01:41PM  Why I Like Exelixis Inc (NASDAQ:EXEL) Simply Wall St.
Jun-14-18 08:10AM  Consolidated Research: 2018 Summary Expectations for Rayonier Advanced Materials, CYS Investments, Avid Bioservices, American Airlines Group, Exelixis, and International Business Machines Fundamental Analysis, Key Performance Indications GlobeNewswire
Jun-05-18 04:05PM  Exelixis to Present at the William Blair & Co. 38th Annual Growth Stock Conference on June 12, 2018 Business Wire
Jun-04-18 08:20AM  Today's Research Reports on Trending Tickers: Exelixis and Celgene ACCESSWIRE
Jun-03-18 09:00AM  Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018 Business Wire
Jun-01-18 02:42PM  Intrinsic Calculation For Exelixis Inc (NASDAQ:EXEL) Shows Investors Are Overpaying Simply Wall St.
08:00AM  Exelixis Announces Further Expansion to Clinical Research Protocol for Phase 1b COSMIC-021 Trial of Cabozantinib in Combination with Anti-PD-L1 Immunotherapy in Patients with Locally Advanced or Metastatic Solid Tumors Business Wire
May-30-18 08:14AM  Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA Benzinga
May-29-18 04:05PM  Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX® (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma Business Wire
May-26-18 11:07AM  The Week Ahead In Biotech: ASCO Presentations In The Spotlight Benzinga
May-23-18 02:29PM  Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx Zacks
08:00AM  Today's Research Reports on Trending Tickers: Tesaro and Exelixis ACCESSWIRE
May-22-18 04:15PM  Exelixis Appoints Andrew R. Peters to Newly Created Position of Vice President, Strategy Business Wire
May-21-18 07:10AM  Wired News EU Approved Exelixis/Ipsens CABOMETYX in Europe for Intermediate - or Poor-Risk Advanced Renal Cell Carcinoma ACCESSWIRE
May-19-18 09:12AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
May-17-18 09:35AM  Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer Zacks +5.63%
08:27AM  Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More Benzinga
01:01AM  Exelixis Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma Business Wire
May-16-18 08:40AM  Are Options Traders Betting on a Big Move in Exelixis (EXEL) Stock? Zacks
May-11-18 06:58PM  Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally. Zacks +5.33%
09:30AM  Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day Zacks
08:39AM  Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter Zacks
08:39AM  Array BioPharma (ARRY) in Focus: Stock Moves 5.5% Higher Zacks
08:16AM  3 Healthcare Stocks Growing Over 100% Motley Fool
06:00AM  Bull of the Day: Exelixis (EXEL) Zacks
May-10-18 05:00PM  This Biotech Stock Crashed On Colon Cancer Flop With Roche Investor's Business Daily -14.43%
04:32PM  Why Booking Holdings, Exelixis, and L Brands Slumped Today Motley Fool
03:33PM  Hospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings Zacks
03:03PM  Why Exelixis Dropped Today Motley Fool
08:47AM  5 Winning Stocks With Superb Efficiency Level Zacks
01:01AM  Exelixis Provides Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or Metastatic Colorectal Cancer Business Wire
May-09-18 08:47AM  Prothena (PRTA) Q1 Loss Wider Than Expected, Sales Miss Zacks
May-08-18 04:05PM  Exelixis to Present at the Bank of America Merrill Lynch Health Care Conference on May 15, 2018 Business Wire
09:59AM  Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag Zacks
May-07-18 11:45AM  Edited Transcript of EXEL earnings conference call or presentation 2-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-04-18 04:06PM  Exelixis Reaccelerates Growth Motley Fool
May-03-18 07:03PM  Cramer's lightning round: Don't buy Monster Beverageit's... CNBC Videos +7.76%
Exelixis, Inc., a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. It also offers COTELLIC tablets, an inhibitor of MEK in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited, and Invenra, Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaPres, Prod Dev & Med Aff & CMOOct 01Option Exercise5.0412,00060,480340,288Oct 03 08:08 PM
MORRISSEY MICHAELPresident and CEOOct 01Option Exercise5.0412,50163,005137,501Oct 03 08:11 PM
SCANGOS GEORGE ADirectorOct 01Sale17.8625,000446,5001,536,981Oct 03 08:12 PM
MORRISSEY MICHAELPresident and CEOOct 01Sale17.8212,501222,768125,000Oct 03 08:11 PM
Schwab GiselaPres, Prod Dev & Med Aff & CMOOct 01Sale17.7712,000213,240328,288Oct 03 08:08 PM
SCANGOS GEORGE ADirectorSep 24Sale16.8525,000421,2501,561,981Sep 26 07:40 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 04Option Exercise5.5022,500123,750350,788Sep 06 08:00 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 04Sale18.5322,500416,925328,288Sep 06 08:00 PM
MORRISSEY MICHAELPresident and CEOAug 20Option Exercise5.5090,000495,000215,000Aug 22 08:10 PM
MORRISSEY MICHAELPresident and CEOAug 20Sale17.8290,0001,604,216125,000Aug 22 08:10 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 17Option Exercise5.5150,000275,500328,288Aug 20 08:10 PM
MARCHESI VINCENT TDirectorAug 15Option Exercise3.3840,000135,200173,850Aug 17 07:39 PM
MARCHESI VINCENT TDirectorAug 15Sale19.5040,000780,000133,850Aug 17 07:39 PM
SCANGOS GEORGE ADirectorAug 10Option Exercise4.85108,333525,3321,586,981Aug 10 09:25 PM
MORRISSEY MICHAELPresident and CEOAug 09Option Exercise1.7034,26758,254159,267Aug 09 07:35 PM
MORRISSEY MICHAELPresident and CEOAug 09Sale20.9134,267716,523125,000Aug 09 07:35 PM
MORRISSEY MICHAELPresident and CEOAug 08Option Exercise1.70100,000170,000225,000Aug 09 07:35 PM
MORRISSEY MICHAELPresident and CEOAug 08Sale21.02100,0002,102,000125,000Aug 09 07:35 PM
MORRISSEY MICHAELPresident and CEOAug 07Option Exercise1.70100,000170,000225,000Aug 09 07:35 PM
MORRISSEY MICHAELPresident and CEOAug 07Sale21.10100,0002,110,000125,000Aug 09 07:35 PM
Haley Patrick J.Sr. Vice President, CommercialAug 06Sale20.922,36149,392124,917Aug 08 07:26 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 01Option Exercise5.5022,500123,750300,788Aug 03 07:13 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 01Sale20.5622,500462,600278,288Aug 03 07:13 PM
MORRISSEY MICHAELPresident and CEOJul 16Option Exercise5.5090,000495,000215,000Jul 17 08:19 PM
MORRISSEY MICHAELPresident and CEOJul 16Sale21.1390,0001,901,700125,000Jul 17 08:19 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOJul 02Option Exercise5.5022,500123,750300,788Jul 03 09:07 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOJul 02Sale21.2022,500477,000278,288Jul 03 09:07 PM
MORRISSEY MICHAELPresident and CEOJun 25Option Exercise5.5090,000495,000215,000Jun 27 08:12 PM
MORRISSEY MICHAELPresident and CEOJun 25Sale19.6290,0001,765,800125,000Jun 27 08:12 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOJun 01Option Exercise5.5022,500123,750300,788Jun 01 07:58 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOJun 01Sale20.8022,500468,000278,288Jun 01 07:58 PM
Hessekiel JeffreyEVP and General CounselMay 31Sale20.7165,0001,346,150254,450Jun 01 08:00 PM
FELDBAUM CARL BDirectorMay 30Option Exercise4.2614,75062,79549,483Jun 01 07:59 PM
FELDBAUM CARL BDirectorMay 30Sale20.6034,262705,79715,221Jun 01 07:59 PM
MORRISSEY MICHAELPresident and CEOMay 24Option Exercise5.5090,000495,000215,000May 24 08:16 PM
MORRISSEY MICHAELPresident and CEOMay 24Sale20.5590,0001,849,500125,000May 24 08:16 PM
WILLSEY LANCEDirectorMay 22Sale21.4050,0001,070,000418,273May 24 08:24 PM
Haley Patrick J.Sr. Vice President, CommercialMay 18Sale21.613,66379,157127,278May 18 08:02 PM
SCANGOS GEORGE ADirectorMay 15Option Exercise11.6615,000174,9001,478,648May 16 07:59 PM
MARCHESI VINCENT TDirectorMay 11Option Exercise11.6615,000174,900140,913May 11 07:58 PM
MARCHESI VINCENT TDirectorMay 11Sale19.0315,000285,450125,913May 11 07:58 PM
COHEN CHARLESDirectorMay 09Option Exercise11.6615,000174,900263,180May 10 08:03 PM
COHEN CHARLESDirectorMay 09Sale21.4215,000321,300248,180May 10 08:03 PM
PAPADOPOULOS STELIOSDirectorMay 07Option Exercise11.6615,000174,9001,049,314May 07 08:07 PM
Haley Patrick J.Sr. Vice President, CommercialMay 07Option Exercise1.9015,00028,500145,941May 07 08:06 PM
PAPADOPOULOS STELIOSDirectorMay 07Sale22.1515,000332,2501,034,314May 07 08:07 PM
Haley Patrick J.Sr. Vice President, CommercialMay 07Sale22.0015,000330,000130,941May 07 08:06 PM
Haley Patrick J.Sr. Vice President, CommercialMay 04Option Exercise1.9010,00019,000143,490May 07 08:06 PM
Haley Patrick J.Sr. Vice President, CommercialMay 04Sale22.3812,549280,847130,941May 07 08:06 PM
Hessekiel JeffreyEVP and General CounselMay 04Sale22.3620,000447,200319,450May 07 08:07 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 03Option Exercise5.5022,500123,750300,788May 04 07:06 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 03Sale23.0922,500519,417278,288May 04 07:06 PM
Hessekiel JeffreyEVP and General CounselApr 27Option Exercise1.7025,00042,500339,450Apr 30 08:23 PM
Haley Patrick J.Sr. Vice President, CommercialApr 24Option Exercise1.7020,00034,000133,490Apr 26 08:22 PM
WYSZOMIERSKI JACK LDirectorApr 16Option Exercise9.8230,000294,450108,803Apr 18 08:12 PM
Garber Alan MDirectorApr 16Option Exercise11.6615,000174,90076,329Apr 18 08:11 PM
WYSZOMIERSKI JACK LDirectorApr 16Sale20.2514,959302,92093,844Apr 18 08:12 PM
Garber Alan MDirectorApr 16Sale20.2515,000303,75061,329Apr 18 08:11 PM
MORRISSEY MICHAELPresident and CEOApr 11Option Exercise5.5090,000495,000221,653Apr 13 08:09 PM
MORRISSEY MICHAELPresident and CEOApr 11Sale20.7890,0001,870,200131,653Apr 13 08:09 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOApr 06Option Exercise7.1814,591104,763277,280Apr 06 07:48 PM
MARCHESI VINCENT TDirectorMar 06Option Exercise7.9715,000119,550140,913Mar 07 07:23 PM
MARCHESI VINCENT TDirectorMar 06Sale24.7315,000370,950125,913Mar 07 07:23 PM
FELDBAUM CARL BDirectorMar 05Option Exercise11.6611,000128,26045,733Mar 07 07:26 PM
COHEN CHARLESDirectorMar 05Option Exercise7.9715,000119,550263,180Mar 07 07:25 PM
FELDBAUM CARL BDirectorMar 05Sale23.8811,000262,68034,733Mar 07 07:26 PM
COHEN CHARLESDirectorMar 05Sale24.2315,000363,450248,180Mar 07 07:25 PM
PAPADOPOULOS STELIOSDirectorMar 02Option Exercise7.9715,000119,5501,049,314Mar 02 08:03 PM
WILLSEY LANCEDirectorMar 02Option Exercise9.8230,000294,450498,273Mar 02 08:01 PM
PAPADOPOULOS STELIOSDirectorMar 02Sale24.0515,000360,7501,034,314Mar 02 08:03 PM
WILLSEY LANCEDirectorMar 02Sale23.9130,000717,300468,273Mar 02 08:01 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 01Option Exercise4.427,29332,235262,689Mar 02 08:04 PM
Haley Patrick J.Sr. Vice President, CommercialFeb 28Option Exercise2.5813,62535,200158,519Mar 02 08:00 PM
POSTE GEORGEDirectorFeb 28Option Exercise11.6615,000174,90098,398Mar 02 07:59 PM
Haley Patrick J.Sr. Vice President, CommercialFeb 28Sale27.1345,0291,221,637113,490Mar 02 08:00 PM
POSTE GEORGEDirectorFeb 28Sale26.2615,000393,90083,398Mar 02 07:59 PM
Garber Alan MDirectorJan 09Option Exercise7.9711,50091,65572,829Jan 10 07:27 PM
Garber Alan MDirectorJan 09Sale30.0011,500345,00061,329Jan 10 07:27 PM
Garber Alan MDirectorJan 08Option Exercise7.973,50027,89564,829Jan 10 07:27 PM
Garber Alan MDirectorJan 08Sale31.293,500109,51561,329Jan 10 07:27 PM